Lineage Cell Therapeutics, Inc. · AMEX:LCTX
Lineage Cell Therapeutics — BioTime — Investor Presentation (June 2017)
31 slides from Lineage Cell Therapeutics's investor presentation, Jun 29, 2017
Slide 1: Leading the Regenerative Medicine Revolution
ie = BIOTIME Leading the Regenerative Medicine Revolution NYSE MKT: BTX se June 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not
Slide 3: BioTime Investment Considerations
BIOTIME Investment Considerations Multiple Programs @ Various Stages of Development > Not dependent on only one program or technology » Late-Stage — Near Commercial Product > Renevia & Lung Cancer Dx could be commercial w/in 1 yr - Large Market Opportunities + Renevia (Aesthetics) addresses 1.5M pro
Slide 4: 2H '17 Milestones
1H ‘17 2H ‘17 017 Milestones OpRegen® + Data at ARVO + US Clinical Trial Site Initiation + Seeking DSMB Approval to Start Cohort 3 OpRegen® + Report Month Cohort 2 Data + Complete Cohort 3 + Data from early Cohort 3 + Seeking DSMB Approval 10 Proceed to Cohort 4 Renevia® + Completed Pivotal Trial En
Slide 5: Advancing Regenerative Science
Advancing Regenerative Science mene Dimes Dress Dent Domes Dina Dia ae Retinal Transplant Phase lll Approved/ = BIOTIME
Slide 6: Significant Need for Cell Delivery Matrix
°: Significant Need for Cell Delivery Matrix Living Cells, ————» Hyaluronic Acid ——e, Collagen —+ ff 3-Dimensional Cell Delivery Matrix * Localizes transplanted cells at the intended site + Support structure needed for successful cell engraftment & survival Polymerization Over Time 3-D Living Tissue
Slide 7: Renevia-02: Pivotal Trial Design
Renevia-02: Pivotal Trial Design - Multicenter, randomized, controlled trial PRIMARY ENDPOINT Increase in hemifacial volume as measured by 3D image scan at 6 months, compared to untreated patients Treatment Group > aaoo8 2-6--o- N<8 No Immediate Surgery pee Delayed Treatment Group BIOTIME
Slide 8: Topline Data: Mean Incremental Hemifacial Volume Over Time
Topline Data: Mean Incremental Hemifacial Volume Over Time Mean Incremental Hemifacial Volume @) 2 an —=Renevia 100% Retention 3 —©Control atEMe ‘Transplanted Volume Baseline 1.Mo 3.Mo &Mo 2 & = p<0.001 Serious Adverse Events Procedure arm: None Control arm: 1 out of 30 (3.3%) BIOTIME
Slide 9: Run-In Patients: High rate of implanted volume at 12-months
Run-In Patients: High rate of implanted volume at 12-months Mean Hemifacial Incremental Volume ‘Mean nremertal Volume (c) BE 93% Retention soo at 12-Mo + Run-in patients (n=7 at 12-months) — patients in which the transplant technique was ‘practiced’ at each of the clinical sites * Incremental volume
Slide 10: Renevia: Beyond HIV-Related Facial Lipoatrophy
Renevia’: Beyond HIV-Related Facial Lipoatrophy * Designed to regenerate 3-D adipose tissue * Renevia’ — Potential for long- lasting and “natural” outcome 4 by potentially enabling the growth of new facial tissue *Renevia’ could enable true i regenerative aesthetics Illustration Only: Age-Related Ui
Slide 11: Renevia: A flexible platform for plastic surgeons
Renevia: A flexible platform for plastic surgeons As flexible facial implant platform, Renevia could be a compelling ‘exclusive’ platform for Plastic Surgeons fuse | Description | Potential Benefits + Renevia combined with SVF + Same procedure as pivotal trial Renevia + SVF + Renevia combined with m
Slide 12: Renevia Market Potential
Renevia® Market Potential Renevia’ could replace facial fat transfers and be utilized as an 460,000: | ~41,850,000 add-on with other cosmetic procedures (20% of entire ‘Dermal Filer wi} 220,000 Renevia may also prove to have utility in other reconstructive or ‘augmentation procedures beyond just the
Slide 13: Renevia: Next Steps
Renevia®: Next Steps [Assitional 12-Me and Additional Data [Study Data Aronowitz IIS [Lull Study ICE Mark Filing US and Row Dev Plans * An investigator-initiated study to assess greater Reneviat+SVF volumes in a non-HIV population ~ Investigator — Joel Aronowitz, MD, Diplomate American Board of Plas
Slide 14: Renevia in Facial Aesthetics
Renevia’ in Facial Aesthetics Complete pivotal EU HIV-LA trial — 1H17 iF] File for EU CE mark approval with HIV data 2H17 Data from treatment of non HIV facial fat loss ‘orea, China, US and beyond IOTIME
Slide 15: OpRegen Overview
OpRegen® Overview CELL REPLACEMENT IN DRY AGE-RELATED MACULAR DEGENERATION (DRY-AMD) Loss of RPE cells in the eye may cause both dry or wet AMD The leading cause of blindness in people over age 60 OpRegen®: off-the-shelf injection as a one-time therapy Photoreceptors OpRegen® cells integrate into su
Slide 16: OpRegen cell replacement therapy may repair the damaged retina in dry-AMD
OpRegen® cell replacement therapy may repair the damaged retina in dry-AMD Normal Retina Dry-AMD: Drusen _RPE death, depots Photoreceptor damage RPE organization, QpRegen: RPE cell suspension, Photoreceptor recovery LOT IME
Slide 17: AMD is a progressive disease that could be addressed early with OpRegen
AMD is a progressive disease that could be addressed early with OpRegen ‘OpRegen product Dry AMD natura history ‘degeneration/deficiency Current patient population OpRegen® Patients Possible patients, based on MOA T ME
Slide 18: OpRegen preclinical animal data in RCS rat model
OpRegen preclinical animal data supports structural and functional improvement in RCS rat model. Enhanced Photoreceptor Sparing with OpRegen Enhanced Visual Function Recovel Cone Quantification Optomotor Tracking Thresholds Cones per image (775 um) Peo Pto00—P150 200 x Age ‘Age (days) 160 Long-Term
Slide 19: OpRegen Phase I/IIa: Cohort Ongoing
OpRegen® Phase I/Ila: Cohort 2 Ongoing TRIAL DESIGN PART 1 @ —— P ly: Dose escalation safety and Cohort 1 © 3 Patients efficacy study of OpRegen® transplanted BCVA 20/200 or less . subretinally in patients with advanced dry- —— form of AMD (Geographic Atrophy — GA) Cohort 2 «3 Patient BCVA 20/200 or
Slide 20: OpRegen Data Summary Cohorts and Summary
OpRegen Data Summary Cohorts 1 and 2 Summary * OpRegen to date is well tolerated and has seen no serious adverse effects * Engraftment seen in all patients * Organization and retinal structural recovery noted as well SSS = == 12months None RPE engraftment 2 tp months Posterior capsule opacity RPE en
Slide 21: Patient #3
Patient #3 IOTIME
Slide 22: Patients 1 and 2: Appropriate Engraftment of Cells at Injection Site
poner 1: Appropriate ie rafting of Cells at Injection Site PATIENT 1 PATIENT 2 — SS SHS = = - WEEK POST-OP ‘LEAR POST-OP 6 MONTHS POST-OP 7 MONTHS POST-OP = BIOTIME
Slide 23: Procedural safety continued in Cohort 2
Procedural safety* continued in Cohort 2 a continued to show signs of engraftmen Day 0 Surgery Day 1-FAF Patient 4- Color and FAF ‘No serous averse events seen
Slide 24: OpRegen RPEs can engraft in damaged area
0} Regen RPEs can engraft in damaged area and F fo anize mets a 200k cells) <ul \I 1 month post-op >> 9 month post-op FAF: _hypofluorescent spots observed in lower part of bleb IR: pigmented spots in this area obscure superior part of GA subretinal hyper reflective spots layering in area of retinal
Slide 25: OpRegen in Dry-AMD
OpRegen’ in Dry-AMD Present Cohort 2 date at ARVO, May-17 | Data from Cohorts 1,2 & 3 2H17 DSMB approval to begin cohort 4— Q4 2017 Updated protocol approval for US sites based on safety so far IOTIME
Slide 26: Unlocking Asset Value for BTX Shareholders: Asterias
‘Unlocking Asset Value for BTX Shareholders BioTime owns ~44% (~$77M*) of Asterias (NYSE MKT: AST) a ASTERIAS BIOTHIERAPEUTICS With proprietary, industry-leading platforms based on its pluripotent stem cell and dendritic cell immunotherapy technologies, Asterias is focused on therapies to treat cond
Slide 27: Unlocking Asset Value for BTX Shareholders: OncoCyte
Unlocking Asset Value for BTX S| * BioTime owns ~49% (~$ 78M’) of OncoCyte (NYSE MKT: OCX) Oncocyte~ Focused on non-invasive blood and urine diagnostic tests for early detection of cancer to improve health outcomes through early diagnoses, to reduce the cost of care through the avoidance of more cos
Slide 28: Experienced Leadership Team
Experienced Leadership Team MANAGEMENT Adi Mohanty, Co-Chief Executive Officer 416 years of experience in executive and management positions hire Baxter Michael D. West, Ph.D., Co-Chief Executive Officer 26 years of experience in regenerative medicine and management aGr®/ is oats, deron Russell Skib
Slide 29: Strong Board
Strong Board BOARD OF DIRECTORS Alfred D. Kingsley, Chairman of the Board Partner, Greenway Partners LP. Several Israeli Ventures Deborah Andrews Vice President-Chief Accounting Officer, STAR Surgical Company Neal C. Bradsher, CFA President, Broadwood Capital, Inc Stephen C. Farrell CEO and Director
Slide 30: BioTime Investment Considerations
BIOTIME Investment Considerations Multiple Programs @ Various Stages of Development > Not dependent on only one program or technology » Late-Stage — Near Commercial Product > Renevia & Lung Cancer Dx could be commercial w/in 1 yr . Large Market Opportunities + Renevia (Aesthetics) addresses 1.5M pro
Slide 31: BioTime
= BIOTIME Leading the Regenerative Medicine Revolution NYSE MKT: BTX 1010 Atlantic Ave. #102 Alameda, CA 94501 510-521-3390